Product Name:ethyl N-carbonocyanidoylcarbamate

IUPAC Name:ethyl N-(cyanocarbonyl)carbamate

CAS:68168-42-3
Molecular Formula:C5H6N2O3
Purity:95%+
Catalog Number:CM1044502
Molecular Weight:142.11

Packing Unit Available Stock Price($) Quantity
CM1044502-1g in stock ŴȁƦ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:68168-42-3
Molecular Formula:C5H6N2O3
Melting Point:-
Smiles Code:CCOC(=O)NC(=O)C#N
Density:
Catalog Number:CM1044502
Molecular Weight:142.11
Boiling Point:
MDL No:
Storage:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Resmetirom
Sept. 13, 2023, Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis. 
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD). 
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Resmetirom is the only orally administered, small-molecule, liver-directed, truly β-selective THR agonist in Phase 3 development.